Product: | Gefitinib | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Catalog Number: | 10503 | ||||||||||||
CAS Number: | 184475-35-2 | ||||||||||||
Synonyms: |
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine; Iressa; ZD 1839 |
||||||||||||
Pricing: |
|
||||||||||||
Formula: | C22H24ClFN4O3 | ||||||||||||
Chemical Purity: | 99% plus | ||||||||||||
Molecular Weight: | 446.9 | ||||||||||||
Structure: | |||||||||||||
Appearance: | White to off-white solid | ||||||||||||
Category: | Anti-cancer compounds | ||||||||||||
Stability: | Stable under recommended storage conditions. | ||||||||||||
Storage: |
Keep containers securely sealed when not in use. Glass, polyethylene or polypropylene containers. Check all containers are clearly labeled and free from leaks. Store in impervious break-resistant containers. Should be stored in separate, clearly marked storage areas to minimize the risk of breakage, and to limit contamination in the event of leakage. |
||||||||||||
Transportation: |
IATA: Hazard Class: 9; Un No: UN3077; Packing Group: III; Shipping Name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (CONTAINS GEFITINIB) |
||||||||||||
Literature References: |
Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., Meyerson, M., EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science, 2004, 304(5676):1497-1500. |
||||||||||||
MSDS: | |||||||||||||
Applications: |
Gefitinib is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and has been shown to increase phosphorylation of c-Jun NH2-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) in HaCaT cells. Studies suggest that Gefitinib can enhance keratinocyte apoptosis via an EGFR-independent JNK-activation pathway. Research indicates that Gefitinib can induce apoptosis in several cell lines including, HaCaT cells, KG-1, P39, and primary CD34+ myeloblasts. Erlotinib has similar properties to Gefitinib |